A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period

Type 2 Diabetes Mellitus Clinical Trial

— INITIATION  

Official title:

A 6-month, Multicenter, Prospective, Single-arm, Open-label, Phase IV Study Evaluating the Clinical Efficacy and Safety of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05002933
• Other study ID #: LPS16585
• Secondary ID: U1111-1251-4484
• Status: Completed
• Phase: Phase 4
• Start date: May 20, 2021
• Est. completion date: February 24, 2023

Study information

• Verified date: March 2023
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, interventional, single arm, multicenter, phase 4 study to evaluate the clinical efficacy and safety of initiating Insulin glargine U300 in insulin-naive patients or switching from any other basal insulin to Insulin glargine U300 in insulin pre-treated patients with uncontrolled T2DM.

Description:

Maximum study duration per participant will be approximately 37 weeks per patient: up to 1 week screening period, 24 weeks insulin glargine U300 treatment period and 12 weeks observational extension period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 570
• Est. completion date: February 24, 2023
• Est. primary completion date: February 24, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients (age=18 years) who diagnosed with type 2 diabetes
• Patients who should initiate Insulin glargine U300 treatment following local label and

guideline at investigator's discretion, including:

• insulin naive patients (no current or previous insulin used during the last year prior to screening except for a maximum 10 days in relation to acute illness or surgery, etc.) uncontrolled (HbA1c between 7.5% and 11.0%) at screening visit on stable dose treatment with = 2 OADs (metformin, sulfonylurea, thiazolidinedione, DPP-4 inhibitor, SGLT-2 inhibitor, glinide, a-glucosidase inhibitor) within 8 weeks prior to screening, at least one of which must be on maximum tolerated dose, or
• patients uncontrolled (HbA1c between 7.5% and 11.0%) at screening visit with other basal insulin, or
• patients controlled with other basal insulin but experienced frequent hypoglycemia or with increased hypoglycemia risk at investigator's discretion
• Patients who treated with basal insulin must have a stable dose of antidiabetic drugs (dose change no more than ±20% vs. the dose on screening visit for basal insulin) within 8 weeks prior to screening

Exclusion Criteria:

• Any clinically significant abnormality identified on physical examination, laboratory tests, or vital signs at the time of screening, or at baseline, or any major systemic disease resulting in short life expectancy that in the opinion of the Investigator would restrict or limit the patient's successful participation for the duration of the study
• Use of any product containing short or rapid acting insulin in the last 3 months prior to screening (unless used for =10 days in relation to hospitalization or an acute illness)
• Use of oral anti-diabetic drugs other than those allowed and listed in the inclusion criteria, Glucagon-like peptide-1 (GLP-1) receptor agonists, or any investigational agent (drug, biologic, device) within 3 months prior to screening visit
• Use of systemic glucocorticoids (excluding topical application or inhaled forms) for two weeks or more within 8 weeks prior to the time of screening
• Known hypersensitivity / intolerance to insulin glargine or any of its excipients
• Pregnant or lactating women
• Women of childbearing potential with no effective contraceptive method
• Participation in another clinical trial The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus

Intervention

Drug:
• Insulin glargine 300 U/ml
Solution for injection Subcutaneous injection

Locations

Country	Name	City	State
China	Investigational Sites	China

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change in HbA1c from baseline to week 24		Baseline to Week 24
Secondary	Mean change in HbA1c from baseline to week 12 and week 36		Baseline to Week 12 and 36
Secondary	Percentage of participants achieving HbA1c target <7%		at Week 12, 24 and 36
Secondary	Percentage of participants achieving HbA1c target <7% without hypoglycemic events		at Week 12 and 24
Secondary	Mean change in Fasting Plasma Glucose (FPG) from baseline to week 12, 24 and 36		Baseline to Week 12, 24 and 36
Secondary	Mean change in fasting Self-Monitored Blood Glucose (SMBG) from baseline to week 12 and week 24		Baseline to Week 12 and 24
Secondary	Mean change in of 7-points SMBG per time point from baseline to week 12 and week 24		Baseline to Week 12 and 24
Secondary	Mean change in Insulin glargine U300 dose from baseline to week 12, 24 and 36		Baseline to Week 12, 24 and 36
Secondary	Number of participants experiencing hypoglycemia from baseline to week 12, 24 and 36		Baseline to Week 12, 24 and 36
Secondary	Number of hypoglycemic events per patient-year		Baseline to Week 12, 24 and 36
Secondary	Number of participants with adverse events		Baseline to Week 24 and 36
Secondary	Mean change in body weight from baseline to Week 12 and Week 24		Baseline to Week 12 and 24